| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eee3558418d62167856033c102e5d895 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-624
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2017-02-28^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7556d75020849d19350264e1b1b5896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd412d7866d17b7c15df90fc94b38386 |
| publicationDate |
2018-10-31^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180118746-A |
| titleOfInvention |
Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and their use in the treatment of cancer. |
| abstract |
The present invention relates to the extracellular domain of the alpha chain of receptors for interleukin-7 (IL-7), particularly receptors for human IL-7 expressed in human cells (also designated human IL-7Ralpha or IL-7Ra or CD127) And does not interfere with the IL-7 or TSLP signaling pathway. The antibodies of the present invention do not have an antagonistic effect on the IL-7 receptor, but can still exhibit cytotoxic activity against CD127-positive cells. In a particular embodiment, the antibody has no agonist effect on the IL-7 receptor. |
| priorityDate |
2016-02-29^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |